Clinical-stage pharmaceutical company Plus Therapeutics, Inc. is dedicated to developing, manufacturing, and commercializing cancer and disease treatments. The company's primary focus is on Rhenium-186Re obisbemeda, a patented radiotherapy that specifically targets central nervous system cancers such as recurrent glioblastoma, pediatric brain cancers, and leptomeningeal metastases. Additionally, Plus Therapeutics is developing Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere, an intra-arterial injection designed to treat primary and secondary liver cancers. Plus Therapeutics, Inc. holds license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company, previously known as Cytori Therapeutics, Inc., underwent a name change in July 2019. Founded in 1996, Plus Therapeutics, Inc. is headquartered in Austin, Texas.
Plus Therapeutics's ticker is PSTV
The company's shares trade on the NASDAQ stock exchange
They are based in Austin, Texas
There are 11-50 employees working at Plus Therapeutics
It is plustherapeutics.com
Plus Therapeutics is in the Healthcare sector
Plus Therapeutics is in the Biotechnology industry
The following five companies are Plus Therapeutics's industry peers: